DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available

Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)

History of severe autoimmune disorders requiring use of steroids or other immunosuppressives

Concomitant systemic treatment with chronic use (based on the investigator's judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agents

Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast cancers are allowed

Subjects being treated with a monoamine oxidase inhibitor (MAOI), or drug which has significant MAOI activity (e.g., Meperidine, linezolid, methylene blue) within 3 weeks prior to screening

Subjects who are currently receiving therapy with a potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer or inhibitor (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir)

Use of UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor including: diclofenac, imipramine, and ketoconazole

Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug

Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)

Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study

Lack of availability of a patient for immunological and clinical follow-up assessment

Evidence of current drug or alcohol abuse or psychiatric impairment, which in the Investigator's opinion will prevent completion of the protocol therapy or follow-up

Pregnant or nursing female patients

Unwilling or unable to follow protocol requirements

Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug (i.e., any significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the patient's risk by participating in this study)

Known hypersensitivity to any of the study drugs that will be given to the participant

What this study is about